ATAI | LIFE SCIENCES
310
home,page-template,page-template-full_width,page-template-full_width-php,page,page-id-310,,qode-page-loading-effect-enabled,qode-title-hidden,qode_grid_1300,qode-child-theme-ver-1.0.0,qode-theme-ver-16.4,qode-theme-bridge,wpb-js-composer js-comp-ver-5.6,vc_responsive

The biotech platform to
ultimately cure mental
health disorders.

About us

Leveraging cutting-edge
scientific research and technology

Who we are

ATAI is a global biotech company builder that leverages a decentralized, technology- and data-driven platform model to serve millions of people suffering from mental health disorders.

 

Our mission

We are committed to acquiring and efficiently developing innovative treatments that address significant unmet medical needs and lead to paradigm shifts in the mental health space.

 

Our approach

By pooling expertise, best practices, and resources across our entire portfolio, we mitigate risk and responsibly accelerate the development of impactful and evidence-based treatments.

Focus on
Mental health

ATAI is supporting the revival of treatments with prior evidence in humans, such as psilocybin and ketamine, in fighting mental health disorders

Focus on
Longevity

ATAI is looking into different ways to increase the human healthspan and reverse aging

Focus on
AI & Big Data

ATAI is leveraging the potential of artificial intelligence (AI) and big data analytics to optimize and accelerate the drug development process

Our Strategy

The evolution of biotech
Science fiction becomes reality

Technology has kicked off a new era of biotech, outpacing Moore’s law. We acquire compounds that can benefit from leveraging this technological advancement by developing them on our platform. Compounds that we acquire are in general at an early stage of the drug development process.

We envision to put an end to mental health disorders. To deliver on this vision, we focus on developing solutions for people that suffer from a real unmet medical need – starting with the 320mn patients that suffer from depression.

We believe that small teams are more effective and efficient. Our decentralized and lean setup allows us to constantly spread learning, expertise and best practices across the ATAI platform enabling operational excellence and entrepreneurship.

World-class business and science experts ensure successful execution of acquisitions and pre-clinical & clinical studies in record speed.

Our Team

Vast experience
and great access to deal flow

Christian Angermayer

Founder

Lars Wilde

Co-Founder

Florian Brand

Co-Founder and Chief Executive Officer

Matthias Luz

Chief Medical Officer

Srinivas Rao

Chief Scientific Officer

Danny Talati

Lead, Business Development

Simon Seibold

Associate

Philipp Schreiber

Associate

Our Companies

A portfolio of innovation
Accelerating progress in life sciences

COMPASS Pathways

develops psilocybin therapy for patients with treatment-resistant depression.
compasspathways.com

Perception Neuroscience

develops arketamine therapy for patients with neuropsychiatric diseases.
perceptionneuroscience.com

Innoplexus

leverages the power of AI and big data analytics for a variety of applications in life sciences, like drug development.
innoplexus.com

COMPASS Pathways

develops psilocybin therapy for patients with treatment-resistant depression.
compasspathways.com

Perception Neuroscience

develops arketamine therapy for patients with neuropsychiatric diseases.
perceptionneuroscience.com

Innoplexus

leverages the power of AI and big data analytics for a variety of applications in life sciences, like drug development.
innoplexus.com

Juvenescence

invests in companies with therapies for aging and age-related diseases.
juvenescence.ltd

Insights

Learn about cutting-edge science
and gain life-enhancing insights

Follow us on Twitter and read our blog

Careers

Work with us
to improve the lives of millions of people

WE ARE HIRING! Learn about career opportunities at ATAI and see open jobs across our platform companies.

Let’s stay in touch

Sign up to our newsletter to receive updates on our progress:

75%

A biography (or simply bio) is a detailed description of a person’s life. It involves more than just the basic facts like education, work, relationships.

43%

A biography (or simply bio) is a detailed description of a person’s life. It involves more than just the basic facts like education, work, relationships.

87%

A biography (or simply bio) is a detailed description of a person’s life. It involves more than just the basic facts like education, work, relationships.

Christian Angermayer

Founder

Strategy and investor relations

Lars Wilde

Co-Founder

Advising on drug discovery and compound sourcing

Florian Brand

Co-Founder and Chief Executive Officer

Executing drug development and operations

Simon Seibold

Associate

Investments and business development

Philipp Schreiber

Associate

Drug discovery and compound sourcing

ATAI is supporting the revival of treatments with prior evidence in humans, such as psilocybin and ketamine, in fighting mental health disorders

Depression, anxiety, post-traumatic stress disorder, obsessive-compulsive disorder, bipolar disorder and other psychiatric conditions are increasingly becoming a burden for patients, families and societies.

We believe that

ATAI is leveraging the potential of artificial intelligence (AI) and big data analytics to optimize and accelerate the drug development process

Technological innovation will enable us to consolidate and make sense of vast amounts of previously inaccessible data.

We believe that

Matthias Luz, MD

Chief Medical Officer

Developing clinical strategy for lead compounds

Srinivas Rao, MD, PhD

Chief Scientific Officer

Advance the science into clinical evaluation

Danny Talati

Lead, Business Development

Compound sourcing and evaluating